Cancer Genetics — Q4 2015 Earnings Presentation
10 slides from Cancer Genetics's earnings presentation, Mar 10, 2016
Slide 1: Q4 2015 Earnings Call
March 10, 2016 Q4 2015 Earnings Call Nasdaq (CGIX) THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE
Slide 2: Forward-Looking Statements
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Forward-Looking Statements This slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in
Slide 3: Investor Highlights: Cancer Genetics Addresses the Trends in Oncology
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma Companies CONTRACTS W
Slide 4: 2015 Revenue Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call 2015 Revenue Highlights $18.0M revenue, up 77% Yr./Yr. Biopharma revenue grew 106% Yr./Yr. to $11.6M Year End Total Revenue ($Mn) $4.3 M $6.6 M $10.2 M $18.0 M 2012 2013 2014 2015 43.1% CAGR 22 4th Quarter Total Revenue ($Mn) $5.5M r
Slide 5: Revenues By Category
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call 31% 64% 5% Revenues By Category * Direct Bill includes hospitals or facilities are billed directly by CGI and not through insurance ** 3rd Party Insurers include non-Medicare and non-Medicaid insurers Clinical Services Biopharma Services D
Slide 6: Full year 2015 Financial Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Full year 2015 Financial Highlights FY 2015 revenues were $18.0 million, a 77% increase over FY 2014 revenues of $10.2 million. Revenue from Biopharma Services grew 106%; Clinical Services grew 28%; and Discovery Services grew 412% yea
Slide 7: Q4 2015 Financial Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Q4 2015 Financial Highlights Q4 2015 revenues were $5.5 million, a 36% increase over Q4 2014 revenues of $4.0 million. Revenue from Biopharma Services grew 6%; Clinical Services increased by 106%; and Discovery Services grew 45% year-o
Slide 8: Summary Statement of Operations
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Income Statement Items ($ in Thousands) Q4 2015 Q4 2014 12 mos 2015 12 mos 2014 Revenue $5,484 $4,035 $18,040 $10,199 Gross Profit $728 $941 $3,942 $1,746 Gross Margin (%) 13% 23% 22% 17% Research & Development (R&D) $1,148 $1,529 $5,483 $
Slide 9: Cash Discussion & Overview
Cancer Genetics, Inc. | NASDAQ: CGIX | Q4 2015 Earnings Call Cash Discussion & Overview CASH DISCUSSION (in Millions USD) Q4 2015 Q1 2016 (Expected) Net Loss $ -5.7 $ -4.6 Non Cash Items 1.6 1.7 Loss Excluding Non-Cash Items $ -4.1 $ -2.9 One Time Adjustments - 0.9 0.0 Tax Benefits (From Sale of Net
Slide 10: The Oncology Diagnostics Partner from Bench to Bedside
THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax